Integra LifeSciences - IART Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings or view top-rated stocks.

5 analysts have issued 1-year price targets for Integra LifeSciences' stock. Their IART share price forecasts range from $48.00 to $75.00. On average, they anticipate the company's stock price to reach $58.33 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $56.07 at the beginning of the year. Since then, IART stock has increased by 1.1% and is now trading at $56.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our IART earnings forecast.

Integra LifeSciences will be holding an earnings conference call on Wednesday, February 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Integra LifeSciences Holdings Co. (NASDAQ:IART) posted its earnings results on Monday, November, 1st. The life sciences company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.14. The life sciences company had revenue of $386.86 million for the quarter, compared to the consensus estimate of $384.47 million. Integra LifeSciences had a trailing twelve-month return on equity of 16.41% and a net margin of 11.05%. The business's revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.80 EPS.

Integra LifeSciences shares split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences issued an update on its fourth quarter earnings guidance on Wednesday, January, 25th. The company provided earnings per share (EPS) guidance of $0.92-0.96 for the period, compared to the consensus EPS estimate of $0.90.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Integra LifeSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (0.34%), Fort Washington Investment Advisors Inc. OH (0.27%), National Bank of Canada FI (0.06%), Yousif Capital Management LLC (0.04%), Dupont Capital Management Corp (0.04%) and Comerica Bank (0.04%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IART stock can currently be purchased for approximately $56.68.

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $4.73 billion and generates $1.54 billion in revenue each year. The life sciences company earns $169.07 million in net income (profit) each year or $2.06 on an earnings per share basis.

The company employs 3,800 workers across the globe.

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.